NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
- Conditions
- Cystic FibrosisDiabetes Mellitus
- Interventions
- Other: Stable isotopes
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2018-03-14
- Target Recruit Count
- 42
- Registration Number
- NCT00082238
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00003968
- Locations
- 🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸South Jersey Hospital - Millville, Millville, New Jersey, United States
🇺🇸Riverview Medical Center, Red Bank, New Jersey, United States
Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: apolizumab
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00004101
- Locations
- 🇺🇸
Biologics Evaluation Section, Bethesda, Maryland, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Johns Hopkins Oncology Center, Baltimore, Maryland, United States
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004892
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Biopsy
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00082147
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
- Conditions
- Lip and Oral Cavity CancerHead and Neck CancerOropharyngeal Cancer
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00006106
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00002912
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
- Conditions
- Lymphoma, T-CellLymphoma, Large-Cell, Ki-1
- Interventions
- Drug: UCN-01 (7-hydroxystaurosporine)
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00082017
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00003765
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
- Conditions
- Adenocarcinoma of the ColonStage III Colon Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1260
- Registration Number
- NCT00003835
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States